Takeda Pharmaceutical Company Limited American Depositary Share — Bilancio Trimestrale (NYSE:TAK) | MetaTrader

Apri il grafico completo

Notizie

Takeda Pharmaceutical: The Downside Was Forecastable (NYSE:TAK)

Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test.

Can Asceniv Help ADMA Navigate the Current IG Market Challenges?

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?

Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call Transcript

Relazione sugli utili: Takeda supera le aspettative sull’EPS nel Q4 2025

Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?

Takeda's Rich Pipeline Optionality Is Worth A 'Buy' (NYSE:TAK)

Gli EPS di Takeda Pharma ADR hanno battuto le aspettative per 0,03$, il fatturato appena sotto le previsioni

Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects